Goldman Sachs’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17M Buy
122,300
+74,700
+157% +$10.5M ﹤0.01% 2586
2025
Q4
$5.84M Buy
47,600
+19,600
+70% +$2.38M ﹤0.01% 3602
2025
Q3
$3.11M Buy
28,000
+19,000
+211% +$2.16M ﹤0.01% 4077
2025
Q2
$998K Buy
+9,000
New +$958K ﹤0.01% 4707
2025
Q1
Sell
-10,000
Closed -$924K 6194
2024
Q4
$924K Hold
10,000
﹤0.01% 4876
2024
Q3
$838K Sell
10,000
-30,000
-75% -$2.29M ﹤0.01% 4759
2024
Q2
$2.74M Hold
40,000
﹤0.01% 3685
2024
Q1
$2.93M Buy
40,000
+9,200
+30% +$707K ﹤0.01% 3557
2023
Q4
$2.5M Sell
30,800
-32,500
-51% -$2.53M ﹤0.01% 3753
2023
Q3
$4.74M Sell
63,300
-41,400
-40% -$3.18M ﹤0.01% 3023
2023
Q2
$8.07M Sell
104,700
-80,100
-43% -$6.39M ﹤0.01% 2659
2023
Q1
$15.3M Buy
184,800
+60,200
+48% +$4.99M ﹤0.01% 2040
2022
Q4
$10.7M Buy
124,600
+100,300
+413% +$7.94M ﹤0.01% 2519
2022
Q3
$1.5M Sell
24,300
-1,600
-6% -$101K ﹤0.01% 4210
2022
Q2
$1.6M Sell
25,900
-64,600
-71% -$4M ﹤0.01% 4234
2022
Q1
$5.38M Sell
90,500
-224,400
-71% -$14.3M ﹤0.01% 3286
2021
Q4
$22.9M Buy
314,900
+148,400
+89% +$10.2M ﹤0.01% 1997
2021
Q3
$11.6M Sell
166,500
-318,500
-66% -$22.4M ﹤0.01% 2580
2021
Q2
$33.4M Buy
485,000
+185,100
+62% +$12.4M 0.01% 1617
2021
Q1
$19.4M Sell
299,900
-272,100
-48% -$17.5M ﹤0.01% 1957
2020
Q4
$33.3M Buy
572,000
+137,900
+32% +$8.32M 0.01% 1449
2020
Q3
$27.4M Buy
434,100
+253,400
+140% +$17.6M 0.01% 1489
2020
Q2
$13.9M Sell
180,700
-456,300
-72% -$35M ﹤0.01% 1984
2020
Q1
$47.6M Buy
637,000
+441,100
+225% +$30.5M 0.02% 898
2019
Q4
$12.7M Sell
195,900
-83,400
-30% -$5.43M ﹤0.01% 2249
2019
Q3
$17.7M Sell
279,300
-174,100
-38% -$11.4M 0.01% 1877
2019
Q2
$30.6M Buy
453,400
+78,900
+21% +$5.19M 0.01% 1517
2019
Q1
$24.3M Buy
374,500
+61,100
+19% +$4.06M 0.01% 1712
2018
Q4
$19.6M Sell
313,400
-33,300
-10% -$2.33M 0.01% 1823
2018
Q3
$26.8M Sell
346,700
-351,200
-50% -$26.5M 0.01% 1704
2018
Q2
$49.4M Sell
697,900
-18,700
-3% -$1.32M 0.01% 1217
2018
Q1
$54M Sell
716,600
-457,200
-39% -$36.3M 0.01% 1141
2017
Q4
$84.1M Buy
1,173,800
+21,500
+2% +$1.63M 0.02% 912
2017
Q3
$93.4M Sell
1,152,300
-317,600
-22% -$24.3M 0.02% 857
2017
Q2
$104M Buy
1,469,900
+559,200
+61% +$37.2M 0.03% 735
2017
Q1
$61.9M Sell
910,700
-123,700
-12% -$8.7M 0.02% 1081
2016
Q4
$74.1M Sell
1,034,400
-137,100
-12% -$10.2M 0.02% 986
2016
Q3
$92.7M Sell
1,171,500
-104,000
-8% -$8.45M 0.03% 761
2016
Q2
$106M Buy
1,275,500
+387,900
+44% +$34.4M 0.03% 633
2016
Q1
$81.5M Sell
887,600
-476,700
-35% -$43M 0.03% 771
2015
Q4
$138M Sell
1,364,300
-1,194,000
-47% -$124M 0.04% 508
2015
Q3
$251M Buy
2,558,300
+1,658,700
+184% +$184M 0.08% 235
2015
Q2
$105M Sell
899,600
-1,281,300
-59% -$140M 0.03% 633
2015
Q1
$214M Buy
2,180,900
+308,300
+16% +$31.3M 0.07% 331
2014
Q4
$177M Buy
1,872,600
+785,800
+72% +$81.3M 0.06% 410
2014
Q3
$116M Sell
1,086,800
-267,800
-20% -$26.2M 0.04% 568
2014
Q2
$112M Sell
1,354,600
-2,887,900
-68% -$225M 0.04% 608
2014
Q1
$301M Buy
4,242,500
+1,908,200
+82% +$150M 0.1% 203
2013
Q4
$175M Buy
2,334,300
+438,500
+23% +$30.5M 0.06% 394
2013
Q3
$119M Sell
1,895,800
-487,400
-20% -$29.1M 0.04% 514
2013
Q2
$122M Buy
+2,383,200
New +$124M 0.05% 458

Other funds holding GILD

Goldman Sachs's GILD Position: Q1 2026 in Review

Goldman Sachs increased its Gilead Sciences (GILD) stake by 26% in Q1 2026, buying an estimated $324M and bringing the position to 11,065,214 shares worth $1.54B. The position accounts for 0.18% of the portfolio, ranked #93.

Goldman Sachs first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.35B in Q2 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Goldman Sachs held 11,065,214 shares of Gilead Sciences worth $1.54B as of Q1 2026.
  • Goldman Sachs bought 2,312,701 Gilead Sciences shares in Q1 2026, an estimated $324M.
  • Gilead Sciences made up 0.18% of Goldman Sachs's portfolio in Q1 2026, its #93 holding.
  • Goldman Sachs first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Gilead Sciences position peaked at $2.35B in Q2 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.